JP2000512634A - 下痢の治療 - Google Patents
下痢の治療Info
- Publication number
- JP2000512634A JP2000512634A JP10500810A JP50081098A JP2000512634A JP 2000512634 A JP2000512634 A JP 2000512634A JP 10500810 A JP10500810 A JP 10500810A JP 50081098 A JP50081098 A JP 50081098A JP 2000512634 A JP2000512634 A JP 2000512634A
- Authority
- JP
- Japan
- Prior art keywords
- diarrhea
- reuteri
- administration
- strain
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.若年患者の脱水を効果的にかつ急速にとめる激しい下痢の処置方法にして: a)患者が下痢をおこしているか、今にもおこそうとしているかを決定し、 b)lactobacillus reuteriの菌株を選定し、 C)患者への投与のためおよそ10の7乗乃至10の10乗のセルを含む上記 菌株の少なくとも1分与量を用意し、そして d)下痢診断後直ちに上記患者へ少なくとも1分与量を経口投与することを特 徴とする瀉止方法。 2.セルを凍結乾燥した少なくとも1分与量を用意し、更に凍結乾燥したセルを 液体中に懸濁すること、該凍結乾燥したセルをゼラチンカプセル内に封じること 、及び、上記凍結乾燥したセルを患者投与まで水分不浸透性の容器内へ貯蔵密封 しておくことよりなる群から選ばれたステップを含むことを特徴とする請求の範 囲1記載の瀉止方法。 3.下痢をおこしている哺乳動物を施療する方法にして、 a)患者が下痢をおこしているか、今にもおこそうとしているかを決定し、 b)lactobacillus reuteriの菌株を選定し、 c)哺乳動物への投与のためおよそ10の7乗乃至10の10乗のセルを含む 上記菌株の少なくとも1分与量を用意し、そして d)下痢診断後直ちに上記患者へ少なくとも1分与量を経口投与することを特 徴とする哺乳動物を施療する方法。 4.下痢がなくなるまでおよそ10の8乗のセルを哺乳動物へ1日当たり投与す る前記請求の範囲3に記載の方法。 5.上記凍結乾燥したセルをよりなる少なくとも1分与量を用意することを特徴 とする前記請求の範囲3に記載の方法。 6.投与前に凍結乾燥したセルを液体に懸濁することを特徴とする前記請求の範 囲5に記載の方法。 7.上記液体がジュウス、乳製品及び水よりなる群から選ばれることを特徴とす る前記請求の範囲6に記載の方法。 8.哺乳動物への投与のため上記凍結乾燥したセルがゼラチンカプセル内に封じ こめられていることを特徴とする前記請求の範囲5に記載の方法。 9.上記凍結乾燥したセルを哺乳動物投与まで水分不浸透性の容器内へ貯蔵密封 しておくことを特徴とする請求の範囲5記載の瀉止方法。 10.上記下痢がロタウイルス感染に関係する場合であることを特徴とする前記 請求の範囲3に記載の方法。 11.上記哺乳動物が人類であることを特徴とする前記請求の範囲3に記載の方 法。 12.施療中の哺乳動物と同じ形式の哺乳動物とは上記菌株が隔離されることを 特徴とする前記請求の範囲3に記載の方法。 13.上記菌株が人類とは隔離されることを特徴とする前記請求の範囲3に記載 の方法。 14.上記菌株が人類母乳とは隔離されることを特徴とする前記請求の範囲3に 記載の方法。 15.哺乳動物への投与のためlactobacillus reuteri菌株の少なくともおよそ1 0の7乗の生きたセルを有することを特 徴とする下痢症状緩和用治療薬。 16.上記セルが凍結乾燥され、水分不浸透性の容器に包装されることを特徴と する前記請求の範囲15に記載の治療薬。 17.上記セルが液体中に懸濁されることを特徴とする前記請求の範囲15に記 載の治療薬。 18.上記液体が果物ジュウス、乳製品及び水よりなる群から選ばれることを特 徴とする前記請求の範囲17に記載の治療薬。 19.哺乳動物への投与のため上記凍結乾燥したセルがセラチンカプセル内に置 かれていることを特徴とする前記請求の範囲15に記載の治療薬。 20.上記菌株が人類から隔離され、上記治療薬がヒト用であることを特徴とす る前記請求の範囲15に記載の治療薬。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/658,473 US5837238A (en) | 1996-06-05 | 1996-06-05 | Treatment of diarrhea |
US08/658,473 | 1996-06-05 | ||
PCT/US1997/009626 WO1997046104A1 (en) | 1996-06-05 | 1997-06-03 | Treatment of diarrhea |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010160577A Division JP4861500B2 (ja) | 1996-06-05 | 2010-07-15 | 下痢の処置方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000512634A true JP2000512634A (ja) | 2000-09-26 |
Family
ID=24641378
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10500810A Withdrawn JP2000512634A (ja) | 1996-06-05 | 1997-06-03 | 下痢の治療 |
JP2010160577A Expired - Fee Related JP4861500B2 (ja) | 1996-06-05 | 2010-07-15 | 下痢の処置方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010160577A Expired - Fee Related JP4861500B2 (ja) | 1996-06-05 | 2010-07-15 | 下痢の処置方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US5837238A (ja) |
EP (1) | EP0923293B1 (ja) |
JP (2) | JP2000512634A (ja) |
AT (1) | ATE281840T1 (ja) |
AU (1) | AU734194B2 (ja) |
BR (1) | BR9710689A (ja) |
CA (1) | CA2257077C (ja) |
DE (1) | DE69731540T2 (ja) |
ES (1) | ES2232869T3 (ja) |
PL (1) | PL189998B1 (ja) |
PT (1) | PT923293E (ja) |
WO (1) | WO1997046104A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010280664A (ja) * | 2010-07-02 | 2010-12-16 | Biogaia Ab | ラクトバチルス・リューテリ(Lactobacillusreuteri)株を用いる哺乳類における免疫機能の改善方法 |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6100388A (en) * | 1998-03-16 | 2000-08-08 | Biogaia Biologies Ab | Lactobacilli harboring aggregation gene as a vaccine delivery vehicle |
US6399055B1 (en) * | 1998-10-27 | 2002-06-04 | Compagnie Gervais Danone | Method and composition for treatment of infant diarrhea |
HUP0200374A2 (en) | 1999-03-11 | 2002-06-29 | Nestle Sa | Lactobacillus strains capable of preventing diarrhoea caused by pathogenic bacteria and rotaviruses |
EP1034788A1 (en) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactic acid bacteria strains capable of preventing diarrhea |
EP1034787A1 (en) * | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus strains preventing diarrhea caused by pathogenic bacteria |
US6283294B1 (en) * | 1999-09-01 | 2001-09-04 | Biogaia Biologics Ab | Enclosed living cell dispensing tube |
WO2001098516A2 (en) * | 2000-06-19 | 2001-12-27 | Regents Of The University Of Minnesota | Siderophores-producing bifidobacteria thereby and uses thereof |
AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
KR100437497B1 (ko) * | 2001-03-07 | 2004-06-25 | 주식회사 프로바이오닉 | 로타바이러스 및 유해 미생물 억제 활성을 가지는 신규내산성 락토바실러스 루테리 프로바이오-16 및 이를함유하는 생균활성제 |
US20040071793A1 (en) * | 2002-10-05 | 2004-04-15 | Bobrowski Paul J. | Oral rehydration methods and compositions |
US7105336B2 (en) | 2002-10-07 | 2006-09-12 | Biogaia Ab | Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter |
US20050281756A1 (en) * | 2004-06-14 | 2005-12-22 | Eamonn Connolly | Use of lactic acid bacteria for decreasing gum bleeding and reducing oral inflammation |
US6872565B2 (en) | 2003-01-29 | 2005-03-29 | Biogaia Ab | Product containing Lactobacillus reuteri strain ATTC PTA-4965 or PTA-4964 for inhibiting bacteria causing dental caries |
US7517681B2 (en) * | 2003-01-29 | 2009-04-14 | Biogaia Ab | Selection and use of lactic acid bacteria for reducing dental caries and bacteria causing dental caries |
US20050106267A1 (en) | 2003-10-20 | 2005-05-19 | Framework Therapeutics, Llc | Zeolite molecular sieves for the removal of toxins |
US7955834B2 (en) * | 2004-06-03 | 2011-06-07 | Biogaia Ab | Method for improved breast milk feeding to reduce the risk of allergy |
US20060078546A1 (en) * | 2004-10-07 | 2006-04-13 | Anders Zachrisson | Use of lactic acid bacteria to reduce sick time |
US7344867B2 (en) * | 2005-04-15 | 2008-03-18 | Eamonn Connolly | Selection and use of lactic acid bacteria for reducing inflammation in mammals |
US20060251634A1 (en) * | 2005-05-06 | 2006-11-09 | Ho-Jin Kang | Method of improving immune function in mammals using lactobacillus strains with certain lipids |
US8603460B2 (en) * | 2006-06-05 | 2013-12-10 | Brogaia AB | Method of making a Lactobacillus reuteri with increased acid tolerance |
US7374924B2 (en) * | 2006-06-05 | 2008-05-20 | Biogaia Ab | Use of selected lactic acid bacteria for reducing infantile colic |
US20080254011A1 (en) * | 2007-04-11 | 2008-10-16 | Peter Rothschild | Use of selected lactic acid bacteria for reducing atherosclerosis |
EP1997499A1 (en) * | 2007-05-31 | 2008-12-03 | Puleva Biotech, S.A. | Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis |
US8617537B2 (en) * | 2008-06-10 | 2013-12-31 | Biogaia Ab | Controlled activation of the reuterin-production machinery of lactobacillus |
US20110014324A1 (en) * | 2009-07-10 | 2011-01-20 | Christoffer Lundqvist | Product for the storage of freeze-dried lactic acid bacteria mixed with oral rehydration solution |
EP3181684B1 (en) | 2010-02-01 | 2019-05-29 | Rebiotix Inc. | Bacteriotherapy for clostridium difficile colitis |
US20110293710A1 (en) | 2010-02-02 | 2011-12-01 | Delphine Saulnier | Immunomodulatory properties of lactobacillus strains |
IT1401460B1 (it) * | 2010-06-11 | 2013-07-26 | Probiotical Spa | "ceppi di batteri probiotici produttori di vitamina b12" |
NZ607043A (en) | 2010-08-04 | 2015-05-29 | Borody Thomas J | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
WO2012122478A1 (en) | 2011-03-09 | 2012-09-13 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
US20130022586A1 (en) | 2011-07-21 | 2013-01-24 | James Versalovic | Production and use of bacterial histamine |
GB201206599D0 (en) | 2012-04-13 | 2012-05-30 | Univ Manchester | Probiotic bacteria |
US9719144B2 (en) | 2012-05-25 | 2017-08-01 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
EP2674162A1 (en) * | 2012-05-29 | 2013-12-18 | Danuta Kruszewska | Nanoproduct comprising lactobacillus reuteri dan080 useful in prophylaxis and medicine, both human and veterinary and medical use of the same |
WO2013180585A1 (en) * | 2012-05-29 | 2013-12-05 | Danuta Kruszewska | Nanoproduct comprising lactobacillus reuteri dan080 useful in prophylaxis and medicine, both human and veterinary and medical use of the same |
JP6330032B2 (ja) | 2013-06-05 | 2018-05-23 | レビオティクス インコーポレイテッドRebiotix,Inc. | 微生物叢回復療法組成物を製造、処理、および梱包するための方法 |
US10716850B2 (en) | 2014-12-31 | 2020-07-21 | Wellin, Inc. | Anti-inflammatory factor retentate, method of isolation, and use |
MX2017014488A (es) | 2015-05-14 | 2018-06-11 | Crestovo Holdings Llc | Composiciones para transplante de la flora fecal y metodos para elaborarlos y utilizarlos y dispositivos para suministrarlos. |
DK3297644T3 (da) | 2015-05-22 | 2022-04-11 | Univ Arizona State | Fremgangsmåder til behandling af autismespektrumforstyrrelse og forbundne symptomer |
US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
US11026978B2 (en) | 2016-10-11 | 2021-06-08 | Finch Therapeutics Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders |
US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
CA3058818A1 (en) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating parkinson's disease (pd) and related disorders |
WO2018187464A1 (en) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
AU2018272048B2 (en) | 2017-05-26 | 2024-04-04 | Finch Therapeutics Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
CA3072032A1 (en) | 2017-08-07 | 2019-02-14 | Finch Therapeutics, Inc. | Compositions and methods for maintaining and restoring a healthy gut barrier |
US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
KR20210065969A (ko) | 2018-09-27 | 2021-06-04 | 핀치 테라퓨틱스 홀딩스 엘엘씨 | 간질 및 관련 장애를 치료하기 위한 조성물 및 방법 |
WO2024081219A1 (en) | 2022-10-14 | 2024-04-18 | Csp Technologies, Inc. | Container and method for storing and stabilizing moisture sensitive products |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6289625A (ja) * | 1985-05-29 | 1987-04-24 | パイオニア,ハイ−ブレド、インタ−ナシヨナル、インコ−ポレ−テツド | 動物における胃腸病の治療方法 |
JPH02503385A (ja) * | 1987-05-01 | 1990-10-18 | バイオガイア・バイオロジクス・エイビー | 抗生物質レウテリン |
JPH05292947A (ja) * | 1992-04-17 | 1993-11-09 | Sanei Touka Kk | ラクトバチルス・アシドフィルスpn−ri−2−4、それを用いた乳酸菌製剤及びその製造方法 |
JPH06321807A (ja) * | 1984-02-09 | 1994-11-22 | Royal Children S Hospital Res Found | ロタウイルスワクチンの製造方法 |
US5480641A (en) * | 1990-06-15 | 1996-01-02 | Biogaia Ab | Feed additive which consists of whey and Lactobacillus reuteri and a method of delivering Lactobacillus reuteri to the gastrointestinal tract |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5413960A (en) * | 1987-05-01 | 1995-05-09 | Biogaia Ab | Antibiotic reuterin |
WO1997022353A1 (en) * | 1995-12-21 | 1997-06-26 | Abbott Laboratories | Use of lactobacillus reuteri to inhibit cryptosporidiosis in mammals |
-
1996
- 1996-06-05 US US08/658,473 patent/US5837238A/en not_active Expired - Lifetime
-
1997
- 1997-06-03 BR BR9710689A patent/BR9710689A/pt not_active Application Discontinuation
- 1997-06-03 CA CA002257077A patent/CA2257077C/en not_active Expired - Lifetime
- 1997-06-03 PL PL97330324A patent/PL189998B1/pl unknown
- 1997-06-03 ES ES97926891T patent/ES2232869T3/es not_active Expired - Lifetime
- 1997-06-03 DE DE69731540T patent/DE69731540T2/de not_active Expired - Lifetime
- 1997-06-03 EP EP97926891A patent/EP0923293B1/en not_active Expired - Lifetime
- 1997-06-03 WO PCT/US1997/009626 patent/WO1997046104A1/en active IP Right Grant
- 1997-06-03 PT PT97926891T patent/PT923293E/pt unknown
- 1997-06-03 AT AT97926891T patent/ATE281840T1/de active
- 1997-06-03 AU AU31548/97A patent/AU734194B2/en not_active Expired
- 1997-06-03 JP JP10500810A patent/JP2000512634A/ja not_active Withdrawn
-
2010
- 2010-07-15 JP JP2010160577A patent/JP4861500B2/ja not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06321807A (ja) * | 1984-02-09 | 1994-11-22 | Royal Children S Hospital Res Found | ロタウイルスワクチンの製造方法 |
JPS6289625A (ja) * | 1985-05-29 | 1987-04-24 | パイオニア,ハイ−ブレド、インタ−ナシヨナル、インコ−ポレ−テツド | 動物における胃腸病の治療方法 |
JPH02503385A (ja) * | 1987-05-01 | 1990-10-18 | バイオガイア・バイオロジクス・エイビー | 抗生物質レウテリン |
US5480641A (en) * | 1990-06-15 | 1996-01-02 | Biogaia Ab | Feed additive which consists of whey and Lactobacillus reuteri and a method of delivering Lactobacillus reuteri to the gastrointestinal tract |
JPH05292947A (ja) * | 1992-04-17 | 1993-11-09 | Sanei Touka Kk | ラクトバチルス・アシドフィルスpn−ri−2−4、それを用いた乳酸菌製剤及びその製造方法 |
Non-Patent Citations (6)
Title |
---|
JPN6008056951, RUIZ−PALACIOS,G. et al., "Tolerance and fecal colonization with Lactobacillus reuteri in children fed a beverage with a mixtur", PEDIATRIC RESEARCH, 19960401, Vol.39, No.4, Part 2, p.184 * |
JPN6008056953, FABIA,R. et al, "The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic acid−in", Scand J Gastroenterol, 1993, Vol.28, No.2, p.155−162 * |
JPN6008056955, WOLF,B.W. et al., "Safety and tolerance of Lactobacillus reuteri in healthy adult male subjects.", Microbial Ecology in Health and Disease, 1995, Vol.8, p.41−50 * |
JPN6010000322, ISOLAURI,E. et al, "A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhe", Pediatrics, 1991, Vol.88, No.1, p.90−97 * |
JPN6010000325, RAZA,S. et al, "Lactobacillus GG promotes recovery from acute nonbloody diarrhea in Pakistan", The Pediatric infectious disease journal, 1995, Vol.14, No.2, p.107−111 * |
JPN6010000327, 原田徳蔵他, "乳幼児の便通異常に対するビオラクチス散の使用経験", 診療と新薬, 1985, Vol.22, No.5, p.1287−1290 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010280664A (ja) * | 2010-07-02 | 2010-12-16 | Biogaia Ab | ラクトバチルス・リューテリ(Lactobacillusreuteri)株を用いる哺乳類における免疫機能の改善方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2257077C (en) | 2008-10-07 |
BR9710689A (pt) | 1999-08-17 |
DE69731540T2 (de) | 2005-10-27 |
EP0923293A1 (en) | 1999-06-23 |
US5837238A (en) | 1998-11-17 |
PL189998B1 (pl) | 2005-10-31 |
ES2232869T3 (es) | 2005-06-01 |
JP2010265303A (ja) | 2010-11-25 |
JP4861500B2 (ja) | 2012-01-25 |
PT923293E (pt) | 2005-03-31 |
AU3154897A (en) | 1998-01-05 |
DE69731540D1 (de) | 2004-12-16 |
EP0923293A4 (en) | 2001-11-07 |
EP0923293B1 (en) | 2004-11-10 |
CA2257077A1 (en) | 1997-12-11 |
AU734194B2 (en) | 2001-06-07 |
PL330324A1 (en) | 1999-05-10 |
ATE281840T1 (de) | 2004-11-15 |
WO1997046104A1 (en) | 1997-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000512634A (ja) | 下痢の治療 | |
Shornikova et al. | Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children | |
Chouraqui et al. | Acidified milk formula supplemented with Bifidobacterium lactis: impact on infant diarrhea in residential care settings | |
RU2748839C2 (ru) | Композиции, способы и наборы для стимулирования мукозальной иммунной системы | |
AU2008317000B2 (en) | Probiotic compositions and methods for inducing and supporting weight loss | |
US8496923B2 (en) | Probiotic treatment for infectious gastrointestinal diseases | |
ES2654246T3 (es) | Probióticos metabólicamente activos | |
US20100166721A1 (en) | Probotic compositions and uses thereof | |
AU2005253664B2 (en) | Lactic bacteria and their use in the prevention of diarrhea | |
PERCIVAL | Intestinal health | |
Petreska Ivanovska et al. | Probiotics, prebiotics, synbiotics in prevention and treatment of inflammatory bowel diseases | |
EP2332557A1 (en) | Probiotic lactic acid bacteria | |
Crane | Pro and anti: the biotics of allergic disease | |
RU2729633C2 (ru) | Биологически активная пищевая добавка для профилактики воспалительного заболевания кишечника и функциональных кишечных расстройств и способ ее получения | |
Cotta et al. | Evaluation of the intestinal colonizing potential and immunomodulating capacity of lactobacilli microspheres | |
Faure et al. | Specific IgA to lactic acid bacteria in feces of children consuming milk fermented by yoghurt symbiosis and Lactobacillus casei (Danone strain DN 114 001) | |
BR112020026076A2 (pt) | composições de lactobacillus plantarum e usos das mesmas | |
Yadav Nisha et al. | INTERNATIONAL RESEARCH JOURNAL OF PHARMACY | |
Liou | Formulation studies of lactic acid-producing bacteria for oral administration | |
NZ619099B2 (en) | Probiotic compositions and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040602 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20080403 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080908 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081111 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090210 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090323 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090423 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100119 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100419 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100531 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20100713 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20100809 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20100823 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20100826 |